Australia Records No New Cervical Cancer Diagnoses in Women Under 25: On Track for World-First Elimination

Australia's Groundbreaking Achievement in Cervical Cancer Prevention

Australia has reached a pivotal public health milestone that underscores the power of proactive vaccination and screening strategies. For the first time since national records began in 1982, there were no cervical cancer diagnoses recorded among women under the age of 25 in 2021. This zero-case year in the youngest eligible screening group signals that the country is firmly on track to become the world's first to eliminate cervical cancer as a public health problem by 2035.

Cervical cancer, once a leading cause of death among Australian women, has seen dramatic declines thanks to the nation's pioneering human papillomavirus (HPV) vaccination program launched in 2007 and the transition to more effective HPV-based screening in 2017. These interventions target HPV, the virus responsible for nearly all cervical cancers, preventing infection before it can lead to precancerous changes or tumors.

Understanding Cervical Cancer and the Role of HPV

Cervical cancer develops in the cells of the cervix, the lower part of the uterus that connects to the vagina. It is almost exclusively caused by persistent infection with high-risk types of human papillomavirus (HPV), a common sexually transmitted infection. There are over 100 HPV types, but types 16 and 18 cause about 70% of cervical cancers worldwide, with others contributing to the rest.

Most HPV infections clear naturally within two years, but in some cases, the virus integrates into cervical cells, leading to abnormal growths. If undetected or untreated, these can progress to invasive cancer over 10-20 years. Symptoms often appear late, including abnormal bleeding, pelvic pain, or discharge, making early detection through screening crucial.

In Australia, before widespread interventions, cervical cancer incidence hovered around 10-12 cases per 100,000 women annually. Globally, it remains the fourth most common cancer in women, claiming over 340,000 lives yearly, predominantly in low-resource settings without vaccination or screening programs.

The Birth of Australia's HPV Vaccination Program

Australia made history in April 2007 as the first country to implement a fully funded, national HPV vaccination program using Gardasil, targeting girls aged 12-13 with a school-based catch-up for those up to 26. Boys were added in 2013, recognizing HPV's role in other cancers like anal and oropharyngeal.

The program's success stemmed from high uptake—peaking at 86.6% for females turning 15 in 2020—and the quadrivalent vaccine's protection against four high-risk HPV types (6, 11, 16, 18), later upgraded to nonavalent Gardasil 9 covering nine types. Studies show a 92% drop in vaccine-targeted HPV prevalence among 18-35-year-olds and corresponding reductions in genital warts and precancers.

By vaccinating before sexual debut, Australia created a 'herd immunity' effect, protecting even unvaccinated individuals through reduced transmission.

From Pap Smears to HPV Testing: Screening Evolution

Parallel to vaccination, Australia revolutionized screening. The National Cervical Screening Program (NCSP), launched in 1991 with two-yearly Pap smears from age 18, shifted in December 2017 to five-yearly HPV testing from age 25. This change leverages HPV's long latency, detecting persistent infections earlier with 95% sensitivity vs. Pap's 55%.

Participation reached 78.1% by mid-2025 for ages 25-74, with self-collection options surging—chosen by nearly half, aiding hard-to-reach groups like First Nations women (up 10% in remote areas). High-grade precancer (HSIL) detection fell 21% to 7.5 per 1,000 screened, reflecting vaccination impact.

The Zero Cases Milestone: What It Means

The 2021 data from the Australian Institute of Health and Welfare (AIHW) confirmed zero invasive cervical cancers in women under 25—the screening-eligible group fully vaccinated pre-debut. Incidence in 25-29-year-olds plummeted to 3.4 per 100,000 from 9.3 in 2013.

Overall incidence dropped to 6.3 per 100,000 in 2021 (from 6.6 in 2020), mortality to 1.4 per 100,000. Five-year survival rose to 76.8% (2017-2021), up from 73.9%. This cohort's success validates the strategy: vaccinate young, screen from 25, treat promptly (86.5% high-grade cases within 12 months).

Photo by 0xk on Unsplash

Statistics Telling the Success Story

• HPV 16/18 prevalence: 1.4% in 2024 (28% drop since 2019), 1.0% in 25-29s.
• Vaccination coverage at 15: 81.1% females, 77.9% males (2024), down from peaks but still world-leading.
• Screening lifetime (35-39): 85%, up-to-date 74.2% (decline noted).
• Indigenous gaps: Incidence 11.7/100k (3x national), but screening equity improving via self-collect.

Modeling predicts <4/100k by 2035 if 90% vaccination, 70% screening, 90% treatment—WHO's 90-70-90 targets.

Challenges Ahead: Declining Uptake

Despite triumphs, cracks appear. HPV vaccination fell >6 points to ~80% post-2020, screening up-to-date dipped to 74.2%, with 25% overdue. Only 50% of 25-29s current. Pandemic disruptions, misinformation, access barriers contribute. Prof Julia Brotherton warns: "Future gains could be undermined without revitalizing programs."

Equity persists: Remote/Indigenous rates lag, though self-collection helps (NT up 15%). 'Own It' campaign boosted awareness 45% in targets.

Government Response and Commitments

Assistant Minister Rebecca White announced $59 million for the National Strategy, targeting equity, participation. EPICC partnership aids Indo-Pacific. Focus: School vax revival, data for underserved, monitoring.

Lessons for the World

Australia's model—early vax, HPV screen, equity focus—inspires. WHO praises as blueprint; EPICC exports it regionally. Challenges like hesitancy highlight sustained effort needed globally, where 620k cases/340k deaths yearly occur, mostly unvaccinated/screened.

AIHW NCSP Report 2025 details data driving policy.

Real-World Impacts and Stories

Women like those in vaccinated cohorts avoid precancer procedures; survival nears 80%. First Nations programs via clinics boost uptake. Globally, advocates cite Australia to push vax in low-income nations.

Case: Vaccinated 20s report near-zero HPV positivity, freeing resources for older/high-risk.

Photo by DJ Paine on Unsplash

Looking Ahead: Securing Elimination

To hit 2035, reverse declines: One-dose vax suffices, catch-up to 26 free. Screen from 25 every 5 years; self-collect expands access. Ongoing trials refine boosters; equity via culturally safe services.

Australia's journey proves prevention works—vaccinate, screen, treat.

C4 Elimination Progress Report tracks path.

Actionable Steps for Australians

• Girls/boys 12-13: School vax automatic.
• Missed? GP/pharmacist free to 26.
• Women 25+: HPV test every 5 years; self-collect available.
• Overdue? Book via GP or Healthdirect.
• Support equity: Advocate First Nations access.